Real-time biomarker tracking is unblinding longevity trials
Longevity startups are under fire for 'unblinding' their own clinical trials by allowing participants to track biomarkers in real-time. This feedback loop is creating a psychological bias that threatens to invalidate years of anti-aging research.
Listen in the Fylom app.
Real-time biomarker dashboards allow trial participants to deduce their treatment group, effectively ending traditional double-blinding.
Unhappiness and loneliness can accelerate biological aging by over one and a half years.
Visual feedback loops from health apps often trigger lifestyle changes that blur pharmacological trial results.
The Food and Drug Administration is launching a real-time clinical trials initiative in April twenty twenty-six.
Synthetic control arms may soon replace human placebo groups by using data-driven digital twins.
Traditional aging trials like TAME face funding hurdles because generic drugs like metformin offer low profit.
- 01Intro1 min
- 02The Death of the Blindfold2 min
- 03The Feedback Loop of Bias3 min
- 04The Case of the TAME Trial and Bryan Johnson3 min
- 05Regulatory Reckoning2 min
- 06Outro1 min
Fylom generates episodes like this on any topic you're curious about.
Fylom episodes are researched, written, and voiced by AI. Automated checks help catch inaccuracies, but episodes aren't reviewed by a human and AI can still get things wrong. Treat them as a starting point, not a source of record — more in our accuracy disclaimer.